Advanced Cancer, Metastatic Cancer, Solid Tumors
Conditions
Keywords
Advanced cancer, Metastatic cancer, solid tumors, Melanoma
Brief summary
This is a Phase I safety trial of bifunctional shRNA-STMN1 (pbi-shRNA™STMN1) BIV (bilamellar invaginated vesicle) lipoplex (LP), pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection. Patients with superficially accessible advanced cancer following prior therapies will be entered into the study following a modified dose escalation design based on the demonstrated safety of our previous clinical experience (BB-IND 13744) with the same liposome and vector DNA backbone expressing a different transgene (of which doses up to 7 mg DNA IV/single dose have been administered). Patients will accrue in 4-patient escalation cohorts using a modified Fibronacci escalation schema (100%-50%-33%-33%) at a starting intratumoral dose of 0.010 mg/kg of DNA through a dose of 0.053 mg/kg DNA intratumoral / single dose. Should a single, but not more than two (2), ≥ Grade 3 Dose Limiting Toxicity (DLT) occur in any cohort, following mandated review (see below) an additional two (2) patients will be accrued at that dose (total of six). If more than one ≥ Grade 3 toxicity occurs in any cohort, the preceding dose cohort will be expanded to six (from four) and if \< 2/6 patients experience ≥ Grade 3 toxicity, that dose will be the Phase II recommended dose. Should no ≥ Grade 3 toxicity occur in any cohort (other than Grade 3 local injection site reaction), an additional two (2) patients will be treated at 0.053 mg/kg DNA intratumoral / single dose.
Interventions
BIOLOGICALpbi-shRNA STMN1 LP
This is a Phase I safety trial of bifunctional shRNA-STMN1 (pbi-shRNA™STMN1) BIV (bilamellar invaginated vesicle) lipoplex (LP), pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection. Patients will accrue in 4-patient escalation cohorts using a modified Fibronacci escalation schema at a starting intratumoral dose of 0.010 mg/kg of DNA through a dose of 0.053 mg/kg DNA intratumoral / single dose.
Sponsors
Gradalis, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically confirmed advanced and/or metastatic cancer, and, if limited to a single lesion, not considered a candidate for curative surgery or radiation therapy). 2. Biopsy accessible lesion. 3. Per cohort dose/volume, the volume of the lesion to be injected must be 3x volume of the injectate. 4. Subjects that have completed all acceptable therapies with curative potential that are the current standard of care for their respective diseases. 5. Recovered from all toxicities (≤ Grade 1) related to prior therapies except for alopecia. 6. 1 measurable or evaluable lesion; ≥ 1.8 cm diameter for cohort 1 (see Table 10); injection and biopsy accessible. 7. Age ≥18 years. 8. ECOG performance status (PS) 0-2. 9. Organ and marrow function as defined below: Absolute granulocyte count ≥ 1,500/mm\^3 Platelets ≥ 100,000/mm\^3 Total bilirubin ≤ 1.5x institutional ULN Creatinine ≤ 2.0 mg/dL 10. Ability to understand and the willingness to sign a written informed consent document including permission for pre- and Days 1 and 2 post- injection biopsy and Day 8 injected lesion excision. 11. Negative pregnancy test.
Exclusion criteria
1. Surgery involving general anesthesia, chemotherapy, radiotherapy, or immunotherapy within 3 weeks prior to entering the study. 2. Patient must not have received any other investigational agents within 4 weeks prior to study entry. 3. Patients with known brain metastases unless treated with whole brain radiation and stable for \>/= 2 months or treated with stereotactic radiotherapy only and stable for \>/=1 month. 4. Short term (\<30 days) concurrent systemic steroids ≤0.125 mg/kg prednisone per day (maximum 7.5 mg/day) and bronchodilators (inhaled steroids) are permitted; other steroid regimens and/or immunosuppressives are excluded. 5. Prior malignancy (excluding nonmelanoma carcinomas of the skin) unless in remission for \>/= 2 years. 6. Kaposi's Sarcoma. 7. Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. 8. Patients who are pregnant or nursing. 9. Patients with known HIV. 10. Patients with chronic Hepatitis B and C infection. 11. Patients with uncontrolled diseases.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To determine the safety of intratumoral administration of pbi-shRNA™ STMN1 LP | 1 month | To determine the safety of intratumoral administration of pbi-shRNA™ STMN1 LP in patients with superficial advanced and/or metastatic cancer who have no acceptable form of standard therapy. |
Countries
United States
Outcome results
None listed